We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

125 hedge funds and large institutions have $1.05B invested in Neurocrine Biosciences in 2014 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 40 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $10M | Put options by funds: $7M

31% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 13

18% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 40

3% more funds holding

Funds holding: 121 → 125 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less capital invested

Capital invested by funds: $1.12B → $1.05B (-$77.2M)

Holders
125
Holders Change
+4
Holders Change %
+3.31%
% of All Funds
3.59%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
17
Increased
47
Reduced
40
Closed
13
Calls
$10M
Puts
$7M
Net Calls
+$3.01M
Net Calls Change
-$355K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$12.6M
2
Millennium Management
Millennium Management
New York
+$5.77M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$5.65M
4
TCM
Tekla Capital Management
Massachusetts
+$5.12M
5
CAM
Cormorant Asset Management
Massachusetts
+$4.23M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$15.5M
2
O
OrbiMed
New York
-$10.9M
3
AQR Capital Management
AQR Capital Management
Connecticut
-$3.68M
4
TI
Turner Investments
Pennsylvania
-$3.4M
5
BFA
BlackRock Fund Advisors
California
-$3.26M
Name Holding Trade Value Shares
Change 		Change in
Stake
ZDA
51
Zweig-DiMenna Associates
New York
$1.85M +$1.76M +125,000 New
Aviva
52
Aviva
United Kingdom
$1.85M +$1.76M +124,427 New
D.E. Shaw & Co
53
D.E. Shaw & Co
New York
$1.83M +$1.07M +75,895 +159%
BlackRock
54
BlackRock
New York
$1.8M +$54.5K +3,865 +3%
CCI
55
Columbus Circle Investors
$1.74M +$1.65M +117,140 New
Marshall Wace
56
Marshall Wace
United Kingdom
$1.73M +$1.64M +116,364 New
TA
57
Teachers Advisors
New York
$1.6M +$135K +9,599 +10%
California Public Employees Retirement System
58
California Public Employees Retirement System
California
$1.54M – – –
AGM
59
Alpine Global Management
New York
$1.48M +$1.09M +77,105 +337%
Prudential Financial
60
Prudential Financial
New Jersey
$1.44M +$118K +8,377 +9%
EAM
61
Eventide Asset Management
Massachusetts
$1.43M +$131K +9,300 +11%
AIG
62
American International Group
New York
$1.42M +$118K +8,346 +10%
Wells Fargo
63
Wells Fargo
California
$1.26M +$189K +13,428 +19%
Swiss National Bank
64
Swiss National Bank
Switzerland
$1.25M – – –
ProShare Advisors
65
ProShare Advisors
Maryland
$1.23M -$596K -42,232 -34%
Susquehanna International Group
66
Susquehanna International Group
Pennsylvania
$1.17M -$671K -47,525 -38%
RhumbLine Advisers
67
RhumbLine Advisers
Massachusetts
$1.05M +$54.5K +3,860 +6%
VFA
68
Virtus Fund Advisers
Connecticut
$1.05M +$996K +70,604 New
State Board of Administration of Florida Retirement System
69
State Board of Administration of Florida Retirement System
Florida
$1.04M +$124K +8,772 +14%
RCM
70
RA Capital Management
Massachusetts
$1.02M -$15.5M -1,100,116 -94%
UOC
71
UBS O'Connor
Illinois
$965K -$447K -31,671 -33%
DBG
72
De Burlo Group
Massachusetts
$949K -$24K -1,700 -3%
American Century Companies
73
American Century Companies
Missouri
$934K +$2.88K +204 +0.3%
MLICM
74
Metropolitan Life Insurance Company (MetLife)
New York
$905K +$45.7K +3,236 +6%
NFA
75
Nationwide Fund Advisors
Ohio
$868K +$61.7K +4,375 +8%
1 2
3
4 5

NBIX Hedge Fund Activity: Q2 2014 in Review

125 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2014, worth a combined $1.05B — down 6.9% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new NBIX positions and 13 closed out — a net gain of 4 holders — while 47 added to existing stakes and 40 trimmed.

The largest buyer was Great Point Partners, adding an estimated $12.6M. The largest seller was RA Capital Management, cutting an estimated $15.5M.

  • 125 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2014, up from 121 in Q1 2014.
  • Funds reported $1.05B of Neurocrine Biosciences stock for Q2 2014, down 6.9% quarter-over-quarter.
  • 17 funds opened new Neurocrine Biosciences positions in Q2 2014 and 13 closed out, a net change of +4 holders.
  • The largest Neurocrine Biosciences buyer in Q2 2014 was Great Point Partners, an estimated $12.6M added.
  • The largest Neurocrine Biosciences seller in Q2 2014 was RA Capital Management, an estimated $15.5M sold.

Based on aggregated 13F filings for Q2 2014.